A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
NCT ID: NCT06839105
Last Updated: 2025-05-31
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE1
Total Enrollment
214 participants
Study Classification
INTERVENTIONAL
Study Start Date
2025-02-21
Study Completion Date
2028-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this phase I clinical study was to evaluate the safety and tolerability of AWT020 monotherapy and combination with other antitumor therapies in patients with advanced malignancies
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of XNW28012 in Subjects with Advanced Solid Tumors Who Failed Standard Treatments
NCT06799637
Advanced Solid Tumors
Pancreatic Carcinoma
Ovarian Cancer
+1 more
RECRUITING
PHASE1/PHASE2
Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)
NCT03564691
Neoplasms
COMPLETED
PHASE1
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors
NCT06963502
Advanced Solid Tumors
Colorectal Cancer
Non-Small Cell Lung Cancer
NOT_YET_RECRUITING
PHASE1
A Study to Evaluate ANS014004 in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06328439
Locally Advanced or Metastatic Solid Tumors
RECRUITING
PHASE1
A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer
NCT06492005
Triple-Negative Breast Cancer
RECRUITING
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
SEQUENTIAL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AWT020
If needed, additional descriptive information (including which interventions are administered in each arm) to differentiate each arm from other arms in the clinical trial.
Group Type
EXPERIMENTAL
AWT020
Intervention Type
DRUG
q3w or q2w, i.v.
AWT020 combination with taxol and cisplatin or carboplatin
Group Type
EXPERIMENTAL
Taxol
Intervention Type
DRUG
135\~175 mg/m2, Q3W
Cisplatin or Carboplatin
Intervention Type
DRUG
Cisplatin(75 mg/m2, Q3W) or Carboplatin (AUC=5\~6, Q3W)
AWT020
Intervention Type
DRUG
q3w or q2w, i.v.
AWT020 combination with Pemetrexed and cisplatin or carboplatin
Group Type
EXPERIMENTAL
Cisplatin or Carboplatin
Intervention Type
DRUG
Cisplatin(75 mg/m2, Q3W) or Carboplatin (AUC=5\~6, Q3W)
Pemetrexed
Intervention Type
DRUG
500 mg/m2, Q3W
AWT020
Intervention Type
DRUG
q3w or q2w, i.v.
AWT020 combination with Oxaliplatin,Capecitabine and Bevacizumab
Group Type
EXPERIMENTAL
Oxaliplatin
Intervention Type
DRUG
130 mg/m2, Q3W
Capecitabine
Intervention Type
DRUG
1000 mg/m2, BID, day1-14, oral, q3w
Bevacizumab
Intervention Type
DRUG
7.5 mg/kg, Q3W
AWT020
Intervention Type
DRUG
q3w or q2w, i.v.
AWT020 combination with Renvastinib
Group Type
EXPERIMENTAL
Renvastinib
Intervention Type
DRUG
8mg or 20mg, QD
AWT020
Intervention Type
DRUG
q3w or q2w, i.v.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Taxol
135\~175 mg/m2, Q3W
Intervention Type
DRUG
Cisplatin or Carboplatin
Cisplatin(75 mg/m2, Q3W) or Carboplatin (AUC=5\~6, Q3W)
Intervention Type
DRUG
Pemetrexed
500 mg/m2, Q3W
Intervention Type
DRUG
Oxaliplatin
130 mg/m2, Q3W
Intervention Type
DRUG
Capecitabine
1000 mg/m2, BID, day1-14, oral, q3w
Intervention Type
DRUG
Bevacizumab
7.5 mg/kg, Q3W
Intervention Type
DRUG
Renvastinib
8mg or 20mg, QD
Intervention Type
DRUG
AWT020
q3w or q2w, i.v.
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Both male and female subjects who are at least 18 years old at the time of signing the consent form;
2. Inclusion of patients with advanced malignancies confirmed histologically or cytologically and meeting the following requirements:
* Single-agent dose escalation and expansion phase to include patients with advanced malignant tumors who have failed or are intolerant of standard treatment, or have no standard treatment options;
* Therapeutic effect expansion stage of single drug:
1. NSCLC: histologically or cytologically confirmed, unresectable locally advanced, relapsed, or distant metastatic NSCLC that has progressed after prior treatment with PD-(L)1 antibody and platinum-containing chemotherapy (except after the last dose \> Progression of adjuvant and neoadjuvant therapy within 6 months). Subjects with EGFR or ALK mutations will need to progress with prior treatment with appropriate kinase inhibitors.
2. Melanoma: histologically unresectable stage III or IV melanoma that has progressed after prior chemotherapy and treatment with PD-(L)1 inhibitors (except after the last dose \> Adjuvant and neoadjuvant therapy that progresses within 6 months); Mucosal melanoma does not require prior PD-(L)1 inhibitor therapy.
4. RCC: Histologically confirmed metastatic or unresectable clear cell type of RCC with disease progression after previous treatment with targeted anti-angiogenesis therapy and PD-(L)1 inhibitors.
5. Other advanced malignancies: patients with advanced malignancies who have failed or been intolerant to standard treatment or have no standard treatment options.
* Combination phase:
1. NSCLC: histologically or cytologically confirmed, unresectable locally advanced, relapsed, or distant metastatic NSCLC that has not progressed after prior treatment with PD-(L)1 antibody and platinum-containing chemotherapy (except after the last dose \> Progression of adjuvant and neoadjuvant therapy within 6 months). Subjects carrying EGFR or ALK mutations were allowed to progress on kinase inhibitor therapy with a previous ≤1 line.
3. RCC: Histologically confirmed metastatic or unresectable clear cell RCC with disease progression after previous treatment with anti-angiogenesis targeted therapy and PD-(L)1 inhibitors.
4. Melanoma: histologically unresectable stage III or IV melanoma that has progressed after prior chemotherapy and treatment with PD-(L)1 inhibitors (except after the last dose \> Adjuvant therapy that progresses within 6 months).
5. HCC: Histologically/cytologically confirmed or cirrhotic patients meet the clinical diagnostic criteria for HCC in AASLD, are identified as having stage B (intermediate) or stage C (advanced) BCLC HCC and are not candidates for radical surgery and/or local therapy, and have previously received PD-(L)1 inhibitors and anti-angiogenic targeted therapy progression.
6. Other advanced malignancies: patients with advanced malignancies who have failed or been intolerant to standard treatment, or have no standard treatment options.
3. ECOG score is 0 or 1;
4. Expected survival ≥12 weeks;
5. Have at least one measurable lesion according to RECIST 1.1 evaluation criteria;
6. Good organ function;
7. Fertile female or male subjects must agree to be childfree during the study period until 6 months after the end of the last dose and voluntarily take highly effective contraception with their partner; The serum pregnancy test for WOCBP must be negative within 7 days prior to the first dose and must be non-lactation (specific contraceptive methods and WOCBP definitions are set out in section 10.3);
8. Patients participate voluntarily, give full informed consent, sign written informed consent, and have good compliance.
2. Inclusion of patients with advanced malignancies confirmed histologically or cytologically and meeting the following requirements:
* Single-agent dose escalation and expansion phase to include patients with advanced malignant tumors who have failed or are intolerant of standard treatment, or have no standard treatment options;
* Therapeutic effect expansion stage of single drug:
1. NSCLC: histologically or cytologically confirmed, unresectable locally advanced, relapsed, or distant metastatic NSCLC that has progressed after prior treatment with PD-(L)1 antibody and platinum-containing chemotherapy (except after the last dose \> Progression of adjuvant and neoadjuvant therapy within 6 months). Subjects with EGFR or ALK mutations will need to progress with prior treatment with appropriate kinase inhibitors.
2. Melanoma: histologically unresectable stage III or IV melanoma that has progressed after prior chemotherapy and treatment with PD-(L)1 inhibitors (except after the last dose \> Adjuvant and neoadjuvant therapy that progresses within 6 months); Mucosal melanoma does not require prior PD-(L)1 inhibitor therapy.
4. RCC: Histologically confirmed metastatic or unresectable clear cell type of RCC with disease progression after previous treatment with targeted anti-angiogenesis therapy and PD-(L)1 inhibitors.
5. Other advanced malignancies: patients with advanced malignancies who have failed or been intolerant to standard treatment or have no standard treatment options.
* Combination phase:
1. NSCLC: histologically or cytologically confirmed, unresectable locally advanced, relapsed, or distant metastatic NSCLC that has not progressed after prior treatment with PD-(L)1 antibody and platinum-containing chemotherapy (except after the last dose \> Progression of adjuvant and neoadjuvant therapy within 6 months). Subjects carrying EGFR or ALK mutations were allowed to progress on kinase inhibitor therapy with a previous ≤1 line.
3. RCC: Histologically confirmed metastatic or unresectable clear cell RCC with disease progression after previous treatment with anti-angiogenesis targeted therapy and PD-(L)1 inhibitors.
4. Melanoma: histologically unresectable stage III or IV melanoma that has progressed after prior chemotherapy and treatment with PD-(L)1 inhibitors (except after the last dose \> Adjuvant therapy that progresses within 6 months).
5. HCC: Histologically/cytologically confirmed or cirrhotic patients meet the clinical diagnostic criteria for HCC in AASLD, are identified as having stage B (intermediate) or stage C (advanced) BCLC HCC and are not candidates for radical surgery and/or local therapy, and have previously received PD-(L)1 inhibitors and anti-angiogenic targeted therapy progression.
6. Other advanced malignancies: patients with advanced malignancies who have failed or been intolerant to standard treatment, or have no standard treatment options.
3. ECOG score is 0 or 1;
4. Expected survival ≥12 weeks;
5. Have at least one measurable lesion according to RECIST 1.1 evaluation criteria;
6. Good organ function;
7. Fertile female or male subjects must agree to be childfree during the study period until 6 months after the end of the last dose and voluntarily take highly effective contraception with their partner; The serum pregnancy test for WOCBP must be negative within 7 days prior to the first dose and must be non-lactation (specific contraceptive methods and WOCBP definitions are set out in section 10.3);
8. Patients participate voluntarily, give full informed consent, sign written informed consent, and have good compliance.
Exclusion Criteria
1. Received the following drugs or treatments before the first dose:
1. received chemotherapy, immunotherapy and other anti-tumor therapy or other investigational drugs within 21 days before the first dose, or received oral fluorouracil, small molecule targeted drugs or Chinese medicines with anti-tumor indications within 14 days before the first dose;
2. Major surgery or radiotherapy within 28 days before the first dose (palliative radiotherapy for local bone/brain lesions allowed within 14 days before the first dose), coarse needle puncture biopsy or other minor surgery within 7 days before the start of study therapy, excluding placement of vascular infusion devices;
3. In combination therapy, patients who have been systematically treated with corticosteroids (\> 10 mg prednisone per day or equivalent) or other immunosuppressants for more than 1 week within 2 weeks prior to initial administration are allowed to be treated with inhaled or topical steroids or ≤10 mg/ day systemic prednisone and equivalent doses of similar drugs;
2. There is active central nervous system metastasis. If the patient has received radiotherapy or surgery in the past, imaging examination within 4 weeks before the first medication indicates stable brain metastases without aggravation or new neurological symptoms, hormone therapy has been discontinued 2 weeks before the first medication, and screening is allowed; For meningeal and brainstem metastases, screening is not allowed regardless of treatment.
3. Immune-related adverse events that led to permanent discontinuation occurred during previous immunosuppressive therapy (such as anti-PD -(L)1, CTLA-4, LAG-3 inhibitors, etc.);
4. There are pleural effusion, abdominal effusion or pericardial effusion with clinical symptoms that require repeated treatment (puncture or drainage, etc.);
5. There is a history of interstitial lung disease or a history of non-infectious pneumonia treated with corticosteroids, or imaging evidence of active pneumonia during the screening period;
6. The presence of severe, unhealed or split wounds, active ulcers, or untreated fractures (other than old fractures assessed by the investigator without clinical intervention);
7. Obvious bleeding tendency or severe coagulation dysfunction;
8. Have poorly controlled hypertension (systolic blood pressure ≥150 mmHg and/or diastolic blood pressure \> 100 mmHg), or have a history of hypertensive crisis or hypertensive encephalopathy;
10. Severe infection occurred within 28 days prior to administration in the first study (CTCAE v5.0\> Grade 2), such as severe pneumonia, bacteremia, infection complications that require hospitalization; Active infection requiring intravenous anti-infective therapy or fever of unknown origin \> 38.5℃ occurred within 2 weeks prior to the first study administration (as determined by the investigators, subjects with fever due to tumors could be enrolled);
11. Clinically significant hemoptysis for any reason (such as blood loss reaching or exceeding 50 ml/ day, or accompanied by clinical symptoms such as dyspnea and shortness of breath) or tumor bleeding (such as significant bleeding caused by tumor, manifested as hemoptysis, hematemesis, bloody stool, etc., and the blood loss reaching 50 ml/ day or more) within 1 month before the first medication, Or accompanied by anemia, hypotension, shock and other symptoms);
12. Gastrointestinal perforation, fistula, abdominal abscess, bleeding, or definite bleeding tendency (including but not limited to: severe esophagofundus varicose veins with bleeding risk, locally active digestive ulcer lesions \[may be considered in investigators' assessment of ulcer stability\], persistent positive stool occult blood, etc.) within 6 months before randomization; For patients with persistent positive stool occult blood, if they are patients with colorectal cancer or gastric cancer, and the positive occult blood test is believed to be related to tumor after detailed evaluation (such as local bleeding, ulcers, etc.), gastrointestinal bleeding is stable and does not cause clinical symptoms (such as anemia, hypotension, etc.) under tumor treatment or disease control, they can be considered for inclusion;
13. Severe cardiovascular and cerebrovascular diseases, including but not limited to, History of myocardial infarction, severe/unstable angina pectoris, congestive heart failure (NYHA cardiac function rating ≥2), clinically significant supratrioventricular or ventricular arrhythmia requiring pharmacological intervention, aortic aneurysm requiring surgical repair, any arterial thromboembolism/embolism event, grade 3 or higher (CTCAE) within 6 months prior to administration v5.0) Venous thrombosis/embolism events, transient ischemic attacks, cerebrovascular accidents; Left ventricular ejection fraction (LVEF) by color Doppler ultrasound \< 50%. Corrected QTc\> 480ms (using the Fridericia method, if the QTc is abnormal, it can be detected three times at an interval of 2 minutes, and the average value is calculated);
14. Active autoimmune diseases requiring systemic treatment (such as corticosteroids or immunosuppressive drugs) are present within 2 years prior to initial medication, including but not limited to systemic systemic lupus erythematosus, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, vasculitis, etc. However, only thyroid, adrenal, or hypopituitarism, type 1 diabetes that can be controlled with hormone replacement therapy, psoriasis or vitiligo that does not require systemic treatment, and childhood asthma/allergies that have resolved are eligible for screening;
15. Had suffered from another malignant tumor within 5 years before the first medication; However, local tumors that have been cured are excluded, including cervical carcinoma in situ, skin basal cell carcinoma and prostate carcinoma in situ;
16. Active tuberculosis, hepatitis B (HBsAg positive with HBV DNA higher than 1000 copies /ml or 200 IU/ml), hepatitis C (HCVAb positive with HCV RNA higher than the lower limit of detection);
17. A history of immunodeficiency, including HIV testing positive, or a known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;
18. The presence of other serious physical or mental illnesses or abnormalities in laboratory tests that may increase the risk of participation in the study, affect treatment compliance, or interfere with the study results, patients who are judged by the investigator to be unsuitable for participation in the study.
1. received chemotherapy, immunotherapy and other anti-tumor therapy or other investigational drugs within 21 days before the first dose, or received oral fluorouracil, small molecule targeted drugs or Chinese medicines with anti-tumor indications within 14 days before the first dose;
2. Major surgery or radiotherapy within 28 days before the first dose (palliative radiotherapy for local bone/brain lesions allowed within 14 days before the first dose), coarse needle puncture biopsy or other minor surgery within 7 days before the start of study therapy, excluding placement of vascular infusion devices;
3. In combination therapy, patients who have been systematically treated with corticosteroids (\> 10 mg prednisone per day or equivalent) or other immunosuppressants for more than 1 week within 2 weeks prior to initial administration are allowed to be treated with inhaled or topical steroids or ≤10 mg/ day systemic prednisone and equivalent doses of similar drugs;
2. There is active central nervous system metastasis. If the patient has received radiotherapy or surgery in the past, imaging examination within 4 weeks before the first medication indicates stable brain metastases without aggravation or new neurological symptoms, hormone therapy has been discontinued 2 weeks before the first medication, and screening is allowed; For meningeal and brainstem metastases, screening is not allowed regardless of treatment.
3. Immune-related adverse events that led to permanent discontinuation occurred during previous immunosuppressive therapy (such as anti-PD -(L)1, CTLA-4, LAG-3 inhibitors, etc.);
4. There are pleural effusion, abdominal effusion or pericardial effusion with clinical symptoms that require repeated treatment (puncture or drainage, etc.);
5. There is a history of interstitial lung disease or a history of non-infectious pneumonia treated with corticosteroids, or imaging evidence of active pneumonia during the screening period;
6. The presence of severe, unhealed or split wounds, active ulcers, or untreated fractures (other than old fractures assessed by the investigator without clinical intervention);
7. Obvious bleeding tendency or severe coagulation dysfunction;
8. Have poorly controlled hypertension (systolic blood pressure ≥150 mmHg and/or diastolic blood pressure \> 100 mmHg), or have a history of hypertensive crisis or hypertensive encephalopathy;
10. Severe infection occurred within 28 days prior to administration in the first study (CTCAE v5.0\> Grade 2), such as severe pneumonia, bacteremia, infection complications that require hospitalization; Active infection requiring intravenous anti-infective therapy or fever of unknown origin \> 38.5℃ occurred within 2 weeks prior to the first study administration (as determined by the investigators, subjects with fever due to tumors could be enrolled);
11. Clinically significant hemoptysis for any reason (such as blood loss reaching or exceeding 50 ml/ day, or accompanied by clinical symptoms such as dyspnea and shortness of breath) or tumor bleeding (such as significant bleeding caused by tumor, manifested as hemoptysis, hematemesis, bloody stool, etc., and the blood loss reaching 50 ml/ day or more) within 1 month before the first medication, Or accompanied by anemia, hypotension, shock and other symptoms);
12. Gastrointestinal perforation, fistula, abdominal abscess, bleeding, or definite bleeding tendency (including but not limited to: severe esophagofundus varicose veins with bleeding risk, locally active digestive ulcer lesions \[may be considered in investigators' assessment of ulcer stability\], persistent positive stool occult blood, etc.) within 6 months before randomization; For patients with persistent positive stool occult blood, if they are patients with colorectal cancer or gastric cancer, and the positive occult blood test is believed to be related to tumor after detailed evaluation (such as local bleeding, ulcers, etc.), gastrointestinal bleeding is stable and does not cause clinical symptoms (such as anemia, hypotension, etc.) under tumor treatment or disease control, they can be considered for inclusion;
13. Severe cardiovascular and cerebrovascular diseases, including but not limited to, History of myocardial infarction, severe/unstable angina pectoris, congestive heart failure (NYHA cardiac function rating ≥2), clinically significant supratrioventricular or ventricular arrhythmia requiring pharmacological intervention, aortic aneurysm requiring surgical repair, any arterial thromboembolism/embolism event, grade 3 or higher (CTCAE) within 6 months prior to administration v5.0) Venous thrombosis/embolism events, transient ischemic attacks, cerebrovascular accidents; Left ventricular ejection fraction (LVEF) by color Doppler ultrasound \< 50%. Corrected QTc\> 480ms (using the Fridericia method, if the QTc is abnormal, it can be detected three times at an interval of 2 minutes, and the average value is calculated);
14. Active autoimmune diseases requiring systemic treatment (such as corticosteroids or immunosuppressive drugs) are present within 2 years prior to initial medication, including but not limited to systemic systemic lupus erythematosus, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, vasculitis, etc. However, only thyroid, adrenal, or hypopituitarism, type 1 diabetes that can be controlled with hormone replacement therapy, psoriasis or vitiligo that does not require systemic treatment, and childhood asthma/allergies that have resolved are eligible for screening;
15. Had suffered from another malignant tumor within 5 years before the first medication; However, local tumors that have been cured are excluded, including cervical carcinoma in situ, skin basal cell carcinoma and prostate carcinoma in situ;
16. Active tuberculosis, hepatitis B (HBsAg positive with HBV DNA higher than 1000 copies /ml or 200 IU/ml), hepatitis C (HCVAb positive with HCV RNA higher than the lower limit of detection);
17. A history of immunodeficiency, including HIV testing positive, or a known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;
18. The presence of other serious physical or mental illnesses or abnormalities in laboratory tests that may increase the risk of participation in the study, affect treatment compliance, or interfere with the study results, patients who are judged by the investigator to be unsuitable for participation in the study.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Junshi Bioscience Co., Ltd.
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fujian Cancer Hospital
Fuzhou, Fujian, China
Site Status
RECRUITING
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Site Status
NOT_YET_RECRUITING
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
Site Status
NOT_YET_RECRUITING
The First Affiliated Hospital of Henan University of Science & Technology
Luoyang, Henan, China
Site Status
NOT_YET_RECRUITING
Hubei Cancer Hospital
Wuhan, Hubei, China
Site Status
RECRUITING
Hunan Cancer Hospital
Changsha, Hunan, China
Site Status
RECRUITING
First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Site Status
RECRUITING
The First Hospital of Jilin University
Changchun, Jilin, China
Site Status
NOT_YET_RECRUITING
Liaoning Cancer Hospital & Institute
Shenyang, Liaoning, China
Site Status
NOT_YET_RECRUITING
The First Hospital of China Medical University
Shenyang, Liaoning, China
Site Status
RECRUITING
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China
Site Status
RECRUITING
Yunnan Cancer Hospital
Kunming, Yunnan, China
Site Status
NOT_YET_RECRUITING
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Site Status
NOT_YET_RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
China
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AWT020-001-I
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Real-world Study of the Efficacy and Safety of PD-1 Inhibitors Combined With Chemoradiotherapy in Lung Metastatic Nasopharyngeal Carcinoma
NCT07062484
NOT_YET_RECRUITING
NA
A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors
NCT04801095
UNKNOWN
PHASE1
A Phase I Study of SIM0609 in Adult Participants With Locally Advanced/Metastatic Solid Tumors
NCT07265921
RECRUITING
PHASE1
Study of GV20-0251 in Participants With Solid Tumor Malignancies
NCT07070518
RECRUITING
PHASE1/PHASE2
9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
NCT06592326
RECRUITING
PHASE3
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Metastatic Triple-negative Breast Cancer
NCT02183805
TERMINATED
PHASE2
WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLC
NCT05351320
RECRUITING
PHASE2
A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer
NCT06196736
RECRUITING
PHASE3
A Phase I/II Study to Evaluate XNW34017 in Patients With Advanced or Metastatic Solid Tumor
NCT07327294
NOT_YET_RECRUITING
PHASE1/PHASE2
A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors
NCT06139211
RECRUITING
PHASE1/PHASE2
SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC)
NCT06208033
NOT_YET_RECRUITING
EARLY_PHASE1
Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLC
NCT06837948
NOT_YET_RECRUITING
PHASE2
A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors
NCT05773937
RECRUITING
PHASE1
Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC
NCT04557020
RECRUITING
PHASE3
High Dose Radiation Therapy With Concurrent Chemotherapy in Locally Advanced Non-small Cell Lung Cancer
NCT03598517
UNKNOWN
NA
Concurrent Chemoradiotherapy Combination With Anlotinib for Limited-stage Small Cell Lung Cancer
NCT04882033
UNKNOWN
PHASE1
A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer
NCT06512051
RECRUITING
PHASE1/PHASE2
CVL006 Combination Therapy in Advanced Solid Tumors
NCT07157956
NOT_YET_RECRUITING
PHASE1/PHASE2
Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors
NCT06446388
NOT_YET_RECRUITING
PHASE2
Abraxane in Patients With Visceral Metastases Dominant Metastatic Breast Cancer
NCT02687490
COMPLETED
PHASE2
Phase I/Ib Multiple Ascending Dose Study in China
NCT03523390
COMPLETED
PHASE1
A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma
NCT05302284
RECRUITING
PHASE3
Safety, Tolerability and Pharmacokinetics of TWP-101 in Patients With Advanced Melanoma and Urothelial Carcinoma
NCT04871334
UNKNOWN
PHASE1
Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy
NCT07328841
RECRUITING
PHASE3
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion
NCT06739395
RECRUITING
PHASE2